What can KEYNOTE-905 tell us about treatment before surgery?
Following his presentation at #ESMO2026, Dr. Anders Ullén joins Brian and Tom to discuss the KEYNOTE-905 trial in cisplatin-ineligible muscle-invasive bladder cancer.
The conversation examines neoadjuvant pembrolizumab and enfortumab vedotin plus pembrolizumab (EVP) versus immediate cystectomy, and the questions these approaches raise.
🎙️ Episode 522 of The Uromigos Podcast is now live: https://apple.co/4iCMOiY
#ESMO2026 #Uromigos #BladderCancer #GUOncology
344 浏览 · 4 赞 · 3 转发 · 0 回复
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
https://esmocongress.esmo.org来源：Uromigos · x.com